Request Demo
Recent blog posts
Latest Hotspot
8 min read
Cilostazol/Rosuvastatin Calcium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Cilostazol/Rosuvastatin Calcium: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Clotrimazole/Hydrocortisone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Clotrimazole/Hydrocortisone: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Amivantamab-VMJM/Hyaluronidase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Amivantamab-VMJM/Hyaluronidase: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Acetaminophen/Chlorpheniramine Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Acetaminophen/Chlorpheniramine Maleate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Pitavastatin Calcium/Choline Fenofibrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Pitavastatin Calcium/Choline Fenofibrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Tapentadol Tartrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Tapentadol Tartrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Psilocybin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Psilocybin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Pembrolizumab/Hyaluronidase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Pembrolizumab/Hyaluronidase: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Artiva Biotherapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Artiva Biotherapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Adicet Bio Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Adicet Bio 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Adaptimmune Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Adaptimmune Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Bicycle Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Bicycle Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.